Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO

Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO

ST. PAUL, Minn., Oct. 1 /PRNewswire/ -- Algos Therapeutics Inc., a Minnesota-based global preclinical contract research organization (CRO) today announces the selection of Dr. Ganesh Iyer as its new president and CEO. Dr. Iyer will assume his new responsibilities immediately.

"We were incredibly fortunate to have attracted such a uniquely qualified executive as Dr. Iyer to lead Algos," stated Gary Smaby, Algos Board Chair and managing partner for Quatris Fund, the Company's lead investor. "Dr. Iyer possesses the rare combination of scientific expertise and business acumen needed to lead Algos in the deployment of the Company's new service-based CRO model focused on assisting leading pharmaceutical companies in bringing their technological breakthroughs to the marketplace," adds Mr. Smaby.

Until recently, Dr. Iyer was Director of Strategic Analysis and Business Operations at MDS Pharma Services. Dr. Iyer has over 16 years of strategic and business development experience with prominent biotech and high-tech companies ranging from R&D start-ups to F500 companies, including ZymoGenetics/Novo Nordisk, Xcyte Therapies, SkeleTech, MDS Pharma Services and Microsoft. Dr. Iyer holds a Ph.D. in Chemical Engineering from Purdue University and an M.B.A. from Seattle University.

"I am very excited about joining Algos and look forward to working with an excellent team to achieving our mission and goal to become the premier preclinical in vivo pain research services company," commented Dr. Iyer.

About Algos Therapeutics:

Founded as Algos Therapeutics, Inc. in 2003, the company recently changed its corporate identity to Algos Preclinical Services to reflect its new strategic market positioning as a US-based preclinical, in vivo CRO that provides contract research services to pharmaceutical, biotech and medical device markets. Algos Preclinical supports the development of its customers' products from its facilities in St. Paul, MN USA.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.